Trials / Completed
CompletedNCT02640625
Improving Prognosis in HIV Infection
Adjuvant Mucosal Therapy in HIV-infected Men With Insufficient Response to Antiretroviral Therapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- Male
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the safety of probiotics in cART-treated immunologic non-responder (INR) patients with chronic HIV infection. The secondary objectives are to i) explore the biological effects of probiotics in combined antiretroviral therapy(cART)-treated INR patient with chronic HIV infection, and ii) investigate differences between cART-treated HIV-infected INR and non-INR patients with regards to gut microbial composition and mucosal barrier function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Probiotic compound | Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-03-01
- Completion
- 2017-04-01
- First posted
- 2015-12-29
- Last updated
- 2021-12-06
- Results posted
- 2020-03-27
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT02640625. Inclusion in this directory is not an endorsement.